Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
How well patients respond to their first round of PRRT could determine if they'll benefit from a second round. A large US multicenter study found that patients with neuroendocrine tumors who had longer progression-free survival after initial 177Lu-DOTATATE therapy also fared better during retreatment — with an 86% disease control rate overall and a favorable safety profile.
How well a patient responds to their first round of peptide receptor radionuclide therapy (PRRT) may be the key to deciding who should get a second round. Data from the largest US multicenter PRRT retreatment cohort to date, presented at the 2026 NANETS Multidisciplinary NET Medical Symposium, show that initial progression-free survival (PFS) is a significant predictor of retreatment outcomes in patients with well-differentiated neuroendocrine tumors (WDNETs).
Of 543 patients with somatostatin receptor-positive WDNETs, 98 (18%) underwent retreatment with 177Lu-DOTATATE. The overall disease control rate was 86%, with a manageable safety profile — most toxicities were low-grade hematologic events.
By the Numbers:
Why it matters: Identifying who will benefit most from PRRT retreatment is a critical clinical challenge. This data gives oncologists a practical, evidence-based tool — initial treatment duration — to guide patient selection and optimize outcomes in this complex patient population.
